Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Abstract

Larotrectinib had marked and durable antitumor activity in patients with TRK fusion-positive cancer, regardless of the age of the patient or of the tumor type. (Funded by Loxo Oncology and others; ClinicalTrials.gov numbers, NCT02122913 , NCT02637687 , and NCT02576431 .).

Keywords

Affiliated Institutions

• Olive View-UCLA Medical Center US
• Florida International University US
• University Hospitals of Cleveland US
• The University of Texas MD Anderson Cancer Center US
• St. Jude Children's Research Hospital US
• Seattle Cancer Care Alliance US
• Cancer Research Center US
• Rigshospitalet DK
• Seattle Children's Hospital US
• Cleveland Clinic US
• Massachusetts General Hospital US
• Florida Memorial University US
• South Texas Accelerated Research Therapeutics US
• Loxo Oncology at Lilly (United States) US
• Fred Hutch Cancer Center US
• Stanford University US
• West Virginia University US
• Children's Hospital of Los Angeles US
• Cincinnati Children's Hospital Medical Center US
• Nemours Children's Clinic US
• Dana-Farber Cancer Institute US
• Fox Chase Cancer Center US
• The University of Texas Southwestern Medical Center US
• Dana-Farber/Boston Children's Cancer and Blood Disorders Center US
• Vanderbilt University US
• University of Southern California US
• Cornell University US
• University of Washington US
• West Virginia State University US
• Oregon Health & Science University US
• Abramson Cancer Center
• Memorial Sloan Kettering Cancer Center US
• University of Colorado Anschutz Medical Campus US

Related Publications